A new study suggests that never-seen-before stem cells in the human retina can restore vision in mice with a common eye ...

Jersey City, N.J.-based Character Biosciences has raised $93 million in a series B financing round.  The funding will be used ...

Base editing corrected a mutation that causes macular degeneration, highlighting the potential of gene therapy to treat ...

While research has determined that there is no association between having AMD and then developing Alzheimer's or dementia, ...

Character Biosciences has raised $93m in an oversubscribed Series B funding round to expedite the progression of precision ...

A New Jersey-based biotech is looking to become the main character in the age-related macular degeneration field. | A New Jersey-based biotech is looking to become the main character in the ...

A team of scientists at the National Institutes of Health (NIH) has developed an eye drop that successfully slowed vision ...

A new study found that the Mediterranean diet may lower risk of age-related macular degeneration (AMD). Macular degeneration ...

Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa.

Co-led by new investors aMoon and Luma Group, Bausch + Lomb, Jefferson Life Sciences and others also participated in the funding, which will accelerate the advancement of pipeline precision therapies ...

- Funding will enable lead candidates CTX114 and CTX203 for AMD to enter clinical trials in the next year JERSEY CITY, N.J.--(BUSINESS WIRE)--Character Biosciences, a precision medicine company ...